4例血栓性血小板减少性紫癜的临床分析(2)
 |
| 第1页 |
参见附件(2354KB，2页)。
[3]Sadler JE,Moake JL,Miyata T,et al.Recent advances in thrombotic thrombocytopenic purpura[M].Hematology Am Soc Hematol Educ Program,2004:407-423.
[4]Gerritsen HE,Robles R,Lammle B,et al.Partial amino acid sequence of purified von Willebrand factor-cleaving protease[J].Blood,2001,98(6):1654-1661.
[5]Plaimauer B,Zimmermann K,Volkel D,et al.Cloning,expression,and functional characterization of von Willebrand factor2cleaving protease(ADAMTS 13)[J].Blood,2002,100(10):3626-3632.
[6]韩红,邹萍.血栓性血小板减少性紫癜及其研究进展[J].临床内科杂志,2007,24(2):142-143.
[7]Vesely SK,George JN,Lammle B,et al.ADAMT13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:relation to presenting features and clinical outcomes in aprospectiv ecohort of 142 patients[J].Blood,2003,102(1):60-68.
[8]Studt JD,Hovinga JA,Radonic R,et al.Familial acquired thrombotic thrombocytopenic purpura:ADAMT13 inhibitory autoantibodies in identical twins[J].Blood,2004,103(11):4195-4197.
[9]张德雄,赵少岚,陈莉琳.大剂量地塞米松冲击疗法治疗小儿重症血小板减少性紫癜[J].现代医院,2005,5(2):17-18.
[10]Gutterman LA.Thrombotic thrombocytopenic purpura:prospective treatment with a standandized regimen[J].T ransus Sci,1992,13(1):45-52.
(收稿日期：2011-03-28)
注：“本文中所涉及到的图表、公式、注解等请以PDF格式阅读”
您现在查看是摘要介绍页，详见PDF附件(2354KB，2页)。